Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 14, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 2,300,000 ordinary shares of 25 pence each.
- Repurchase Price: 1,120.52 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.03% of total voting rights).
- Shares in Issue: 5,363,416,269 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,300,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 484,194,158, while the number of shares in issue remains 5,363,416,269. The filing does not provide comparative data against prior periods for these specific metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory compliance with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,363,416,269) for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on total voting rights (9.03%).
- Review the authority granted at the May 23, 2007 Annual General Meeting to ensure the repurchase was within approved limits.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.